Piper Sandler Maintains Overweight on Globus Medical, Lowers Price Target to $100

Benzinga Newsdesk www.benzinga.com Negative 74.3%

Neg 74.3% Neu 0% Pos 0%

Piper Sandler analyst Matt O'Brien maintains Globus Medical (NYSE:GMED) with a Overweight and lowers the price target from $115 to $100.